BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25970341)

  • 1. Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
    Lindegren S; Andrade LN; Bäck T; Machado CM; Horta BB; Buchpiguel C; Moro AM; Okamoto OK; Jacobsson L; Cederkrantz E; Washiyama K; Aneheim E; Palm S; Jensen H; Tuma MC; Chammas R; Hultborn R; Albertsson P
    PLoS One; 2015; 10(5):e0126298. PubMed ID: 25970341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.
    Lopes dos Santos M; Yeda FP; Tsuruta LR; Horta BB; Pimenta AA; Degaki TL; Soares IC; Tuma MC; Okamoto OK; Alves VA; Old LJ; Ritter G; Moro AM
    PLoS One; 2013; 8(7):e70332. PubMed ID: 23936189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.
    Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
    Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
    Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
    Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
    J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
    Frost SH; Bäck T; Chouin N; Hultborn R; Jacobsson L; Elgqvist J; Jensen H; Albertsson P; Lindegren S
    Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
    Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
    BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution of 211At-labeled humanized monoclonal antibody A33.
    Almqvist Y; Steffen AC; Lundqvist H; Jensen H; Tolmachev V; Sundin A
    Cancer Biother Radiopharm; 2007 Aug; 22(4):480-7. PubMed ID: 17803442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
    Gustafsson AM; Bäck T; Elgqvist J; Jacobsson L; Hultborn R; Albertsson P; Morgenstern A; Bruchertseifer F; Jensen H; Lindegren S
    Nucl Med Biol; 2012 Jan; 39(1):15-22. PubMed ID: 21958859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.
    Soares IC; Simões K; de Souza JE; Okamoto OK; Wakamatsu A; Tuma M; Ritter G; Alves VA
    Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):165-72. PubMed ID: 22553815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
    Frost SH; Bäck T; Chouin N; Jensen H; Hultborn R; Jacobsson L; Lindegren S
    Cancer Biother Radiopharm; 2011 Dec; 26(6):727-36. PubMed ID: 22087606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.
    Bäck T; Haraldsson B; Hultborn R; Jensen H; Johansson ME; Lindegren S; Jacobsson L
    Cancer Biother Radiopharm; 2009 Dec; 24(6):649-58. PubMed ID: 20025544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.
    Fischer E; Grünberg J; Cohrs S; Hohn A; Waldner-Knogler K; Jeger S; Zimmermann K; Novak-Hofer I; Schibli R
    Int J Cancer; 2012 Jun; 130(11):2715-21. PubMed ID: 21796623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
    Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
    J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.